Advertisement
News
Subscribe to MDT Magazine News

2011 Annual Meeting of the American Academy of Allergy, Asthma & Immunology

March 21, 2011 12:31 pm | by EurekAlert | Comments

(NIH/National Institute of Allergy and Infectious Diseases) Scientists supported by NIAID are among those presenting their latest research findings at the AAAAI Annual Meeting. For more than 60 years, NIAID has supported allergy and immunology research at US and international institutions...

TOPICS:

CardioMEMS, Inc. Named a TAG Top 10 Innovative Technology Company

March 21, 2011 12:31 pm | by Bio-Medicine.Org | Comments

ATLANTA, March 21, 2011 /- CardioMEMS, Inc ., an Atlanta-based medical technology company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body, today announced that it has been chosen as one of the Top 10 Innovative...

TOPICS:

Earnings Preview: Walgreen Co.

March 21, 2011 11:45 am | by The Associated Press | Comments

Walgreen Co. reports its fiscal second-quarter results before the stock market opens Tuesday.WHAT TO WATCH FOR: The Deerfield, Ill., company is expected to benefit during the quarter from the flu season's much later peak compared with last year. Walgreen said this month that it had administered...

Advertisement

Bluebird bio names first SAB members, expanding clinical trials

March 21, 2011 11:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Bluebird bio, a Cambridge gene-therapy company, appointed its first scientific advisory board (SAB) members today, and said it would expand clinical trials in its lead compounds.

Innophos Holdings, Inc. Declares Dividend of $0.25 Per Share; Increases Rate By 47%

March 21, 2011 10:31 am | by Bio-Medicine.Org | Comments

CRANBURY, N.J., March 21, 2011 /- Innophos Holdings, Inc. (Nasdaq: IPHS ) today announced that its Board of Directors had declared a dividend of $0.25 per share of common stock, payable on April 29, 2011 to holders of record on April 15, 2011.  The new rate represents an increase of...

TOPICS:

Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011

March 21, 2011 10:31 am | by Bio-Medicine.Org | Comments

WELLESLEY HILLS, Mass., March 21, 2011 /- Joseph F. Finn, Jr., C.P.A. ("Finn") Assignee for the Benefit of Creditors of Source Precision Medicine, Inc. d/b/a/ Source MDx ("Source MDx") announced that the foundational patents of Source MDx will be offered for sale on April 29, 2011. Source...

TOPICS:

Energy, security, superconductivity and more at the largest physics meeting of the year

March 21, 2011 9:40 am | by EurekAlert | Comments

(American Physical Society) Press conferences at the 2011 March Meeting of the American Physical Society will feature research on super tough and stretchy materials, devices to aid in homeland security, new economic and social models, barbecue, bucking broncos and cutting-edge...

TOPICS:

Bayer Gets $100M Gender Class Action Headache

March 21, 2011 9:38 am | by Bio-Medicine.Org | Comments

NEWARK, N.J., March 21, 2011 /- Bayer HealthCare Pharmaceuticals was handed a pounding $100 million headache today that even its highly-publicized aspirin is unlikely to relieve.  The law firm of Sanford Wittels & Heisler, LLP, filed a class action complaint in U.S. District...

TOPICS:
Advertisement

Branded Pharmaceutical Websites Continue to Be Most Impactful in Driving Conversions Among Prospects and Patients

March 21, 2011 9:37 am | by Bio-Medicine.Org | Comments

RESTON, Va., March 21, 2011 /- comScore, Inc. (Nasdaq: SCOR ), a leader in measuring the digital world, today released results from its fifth annual Online Marketing Effectiveness Benchmarks for the Pharmaceutical Industry. The study supports previous findings that exposure to online...

TOPICS:

PharmaNet Shares Expertise in Drug Development Outsourcing at the 2011 Partnerships in Clinical Trials Conference

March 21, 2011 7:35 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., March 21, 2011 /- PharmaNet Development Group, Inc., a leading provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, announces its participation at the 19th Annual Partnerships in Clinical Trials Conference...

TOPICS:

Core Essence Secures $11.5 Million Series B Financing

March 21, 2011 7:35 am | by Bio-Medicine.Org | Comments

FORT WASHINGTON, Pa., March 21, 2011 /- Core Essence Orthopaedics, Inc. (Core Essence), a Fort Washington, Penn.-based orthopaedic device company, announced today it has raised $11.5 million in Series B financing. Baird Venture Partners led the round, joined by existing investor NewSpring...

TOPICS:

Alzheimer's Drug Discovery Foundation Supports ADispell Technology with a Grant to Advance Novel Drug Candidates for Alzheimer's Disease

March 21, 2011 7:34 am | by Bio-Medicine.Org | Comments

NEW YORK, March 21, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $170,750 to ADispell Inc. to develop small molecule drugs designed to halt the progression of cognition loss that occurs with Alzheimer's Disease....

TOPICS:

Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit

March 21, 2011 7:32 am | by Bio-Medicine.Org | Comments

LOS ANGELES, March 21, 2011 /- Attorneys from Dallas' Heygood, Orr & Pearson are announcing a Los Angeles Superior Court ruling that will require executives from Watson Pharmaceuticals Inc. (NYSE: WPI ) and its subsidiary companies to testify under oath and produce key documents as...

TOPICS:

Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases

March 21, 2011 7:32 am | by Bio-Medicine.Org | Comments

HARRISBURG, Pa., March 21, 2011 /- Beginning April 1, Highmark Blue Cross Blue Shield (Highmark) will force a number of their insured patients with primary immunodeficiency diseases and other rare disorders to switch their prescription to a single brand of immunoglobulin (IgG - a blood...

TOPICS:

Curis, Genentech announce cancer drug study result

March 21, 2011 6:45 am | by The Associated Press | Comments

Drug developer Curis Inc. said Monday a mid-stage trial of a potential cancer treatment it is studying with Roche's Genentech unit shrank tumors in patients with an advanced form of skin cancer.The treatment, labeled vismodegib, was tested in a study involving 104 patients with advanced basal...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading